CH646604A5 - Composition pharmaceutique a effet prolonge et son procede de fabrication. - Google Patents
Composition pharmaceutique a effet prolonge et son procede de fabrication. Download PDFInfo
- Publication number
- CH646604A5 CH646604A5 CH9281A CH9281A CH646604A5 CH 646604 A5 CH646604 A5 CH 646604A5 CH 9281 A CH9281 A CH 9281A CH 9281 A CH9281 A CH 9281A CH 646604 A5 CH646604 A5 CH 646604A5
- Authority
- CH
- Switzerland
- Prior art keywords
- agent
- release
- composition according
- tablets
- amount
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 230000007774 longterm Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 58
- 239000003795 chemical substances by application Substances 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 26
- 239000001913 cellulose Substances 0.000 claims description 19
- 229920002678 cellulose Polymers 0.000 claims description 19
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 18
- 230000001105 regulatory effect Effects 0.000 claims description 16
- 229940124597 therapeutic agent Drugs 0.000 claims description 16
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 15
- 229960002390 flurbiprofen Drugs 0.000 claims description 14
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 13
- 230000003628 erosive effect Effects 0.000 claims description 13
- 230000001737 promoting effect Effects 0.000 claims description 13
- 229960001680 ibuprofen Drugs 0.000 claims description 12
- 229920002472 Starch Polymers 0.000 claims description 10
- 229920002261 Corn starch Polymers 0.000 claims description 9
- 239000008120 corn starch Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 230000003111 delayed effect Effects 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 230000002035 prolonged effect Effects 0.000 claims description 4
- -1 rice starch Polymers 0.000 claims description 4
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 235000019426 modified starch Nutrition 0.000 claims description 3
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical group CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 2
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 229920000178 Acrylic resin Polymers 0.000 claims description 2
- 239000004368 Modified starch Substances 0.000 claims description 2
- 229920001800 Shellac Polymers 0.000 claims description 2
- 229920002494 Zein Polymers 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
- 239000003456 ion exchange resin Substances 0.000 claims description 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 229920001592 potato starch Polymers 0.000 claims description 2
- 229940100486 rice starch Drugs 0.000 claims description 2
- 239000004208 shellac Substances 0.000 claims description 2
- 229940113147 shellac Drugs 0.000 claims description 2
- 235000013874 shellac Nutrition 0.000 claims description 2
- 239000005019 zein Substances 0.000 claims description 2
- 229940093612 zein Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 150000001242 acetic acid derivatives Chemical class 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229960001419 fenoprofen Drugs 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 238000012153 long-term therapy Methods 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 79
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 235000019589 hardness Nutrition 0.000 description 10
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 10
- 229960004889 salicylic acid Drugs 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 229940099112 cornstarch Drugs 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000843 powder Substances 0.000 description 6
- 230000036765 blood level Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000009434 installation Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 0 CC(C(C(C(*)*C(F)(F)F)I)N)O Chemical compound CC(C(C(C(*)*C(F)(F)F)I)N)O 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000567 anti-anemic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940124344 antianaemic agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 229940075894 denatured ethanol Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- DLWSRGHNJVLJAH-UHFFFAOYSA-N nitroflurbiprofen Chemical compound FC1=CC(C(C(=O)OCCCCO[N+]([O-])=O)C)=CC=C1C1=CC=CC=C1 DLWSRGHNJVLJAH-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11143080A | 1980-01-11 | 1980-01-11 | |
| US06/194,453 US4308251A (en) | 1980-01-11 | 1980-10-17 | Controlled release formulations of orally-active medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH646604A5 true CH646604A5 (fr) | 1984-12-14 |
Family
ID=26808896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH9281A CH646604A5 (fr) | 1980-01-11 | 1981-01-08 | Composition pharmaceutique a effet prolonge et son procede de fabrication. |
Country Status (22)
| Country | Link |
|---|---|
| JP (1) | JPS56103110A (en, 2012) |
| AT (1) | AT374681B (en, 2012) |
| AU (1) | AU542824B2 (en, 2012) |
| BE (1) | BE886998A (en, 2012) |
| CA (1) | CA1140466A (en, 2012) |
| CH (1) | CH646604A5 (en, 2012) |
| DE (1) | DE3100191A1 (en, 2012) |
| DK (1) | DK6181A (en, 2012) |
| ES (2) | ES8205353A1 (en, 2012) |
| FI (1) | FI76927C (en, 2012) |
| FR (1) | FR2473308B1 (en, 2012) |
| GB (1) | GB2067072B (en, 2012) |
| GR (1) | GR73843B (en, 2012) |
| IE (1) | IE50806B1 (en, 2012) |
| IN (1) | IN151913B (en, 2012) |
| IT (1) | IT1221041B (en, 2012) |
| LU (1) | LU83052A1 (en, 2012) |
| NL (1) | NL8100037A (en, 2012) |
| NO (1) | NO156153C (en, 2012) |
| NZ (1) | NZ195933A (en, 2012) |
| SE (1) | SE447450B (en, 2012) |
| ZA (1) | ZA81136B (en, 2012) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2496082A (en) * | 1947-05-24 | 1950-01-31 | Ashenfelter William | Scaffold structure |
| IT1144911B (it) * | 1981-03-19 | 1986-10-29 | Pharmatec Spa | Composizione farmaceutica a rilascio controllato contenente ibuprofen |
| JPS59227817A (ja) * | 1983-06-07 | 1984-12-21 | Toyo Jozo Co Ltd | 持続性経口用ブレデニン製剤 |
| JPH0662404B2 (ja) * | 1983-06-14 | 1994-08-17 | シンテックス・ファーマシユーテイカルズ・インターナシヨナル・リミテツド | 制御放出性ナプロキセンおよびナプロキセンナトリウム錠 |
| ZA836030B (en) * | 1983-08-16 | 1985-02-27 | Verex Lab | Constant order release solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions |
| ZA836031B (en) * | 1983-08-16 | 1985-02-27 | Verex Lab | Constant release rate solid dosage theophylline formulation |
| US4774091A (en) * | 1983-10-14 | 1988-09-27 | Sumitomo Pharmaceuticals Company, Ltd. | Long-term sustained-release preparation |
| US5385738A (en) * | 1983-10-14 | 1995-01-31 | Sumitomo Pharmaceuticals Company, Ltd. | Sustained-release injection |
| EP0138216B1 (en) * | 1983-10-14 | 1993-01-07 | Sumitomo Pharmaceuticals Company, Limited | Sustained-release ifn preparation for parenteral administration |
| US4855134A (en) * | 1983-10-14 | 1989-08-08 | Sumitomo Pharmaceuticals Company, Limited | Sustained-release preparation |
| ATE87469T1 (de) * | 1985-12-27 | 1993-04-15 | Sumitomo Pharma | Verfahren zur herstellung einer formulierung mit verzoegerter freisetzung. |
| GB8601204D0 (en) * | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
| US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
| ZA881301B (en) * | 1987-02-27 | 1989-10-25 | Lilly Co Eli | Sustained release matrix formulations |
| AU6403196A (en) | 1995-06-30 | 1997-02-05 | Baylor University | Polyester/carboxylic acid composite materials |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2953497A (en) * | 1953-06-03 | 1960-09-20 | Howard A Press | Therapeutic tablets |
| BE604564A (en, 2012) * | 1960-06-06 | |||
| US3577514A (en) * | 1968-06-10 | 1971-05-04 | Pfizer | Sustained release pharmaceutical tablets |
| US3773920A (en) * | 1971-07-14 | 1973-11-20 | Nikken Chemicals Co Ltd | Sustained release medicinal composition |
| US3906086A (en) * | 1971-07-19 | 1975-09-16 | Richard G Powers | Timed-release aspirin |
| GB1500300A (en) * | 1975-01-06 | 1978-02-08 | Ciba Geigy Ag | Pharmaceutical preparation for the treatment of circulatory disorders |
| JPS5411226A (en) * | 1977-06-24 | 1979-01-27 | Shin Etsu Chem Co Ltd | Disintegratable granule |
-
1980
- 1980-12-23 IN IN1418/CAL/80A patent/IN151913B/en unknown
- 1980-12-23 NZ NZ195933A patent/NZ195933A/xx unknown
-
1981
- 1981-01-05 AU AU65976/81A patent/AU542824B2/en not_active Ceased
- 1981-01-06 FR FR8100087A patent/FR2473308B1/fr not_active Expired
- 1981-01-07 DE DE19813100191 patent/DE3100191A1/de active Granted
- 1981-01-07 NL NL8100037A patent/NL8100037A/nl not_active Application Discontinuation
- 1981-01-08 BE BE0/203426A patent/BE886998A/fr unknown
- 1981-01-08 GB GB8100522A patent/GB2067072B/en not_active Expired
- 1981-01-08 JP JP157881A patent/JPS56103110A/ja active Pending
- 1981-01-08 ES ES498369A patent/ES8205353A1/es not_active Expired
- 1981-01-08 DK DK6181A patent/DK6181A/da not_active Application Discontinuation
- 1981-01-08 CH CH9281A patent/CH646604A5/fr not_active IP Right Cessation
- 1981-01-09 IT IT47537/81A patent/IT1221041B/it active
- 1981-01-09 AT AT0005481A patent/AT374681B/de not_active IP Right Cessation
- 1981-01-09 CA CA000368219A patent/CA1140466A/en not_active Expired
- 1981-01-09 IE IE36/81A patent/IE50806B1/en unknown
- 1981-01-09 SE SE8100104A patent/SE447450B/sv not_active IP Right Cessation
- 1981-01-09 ZA ZA00810136A patent/ZA81136B/xx unknown
- 1981-01-09 GR GR63828A patent/GR73843B/el unknown
- 1981-01-09 LU LU83052A patent/LU83052A1/fr unknown
- 1981-01-09 NO NO810062A patent/NO156153C/no unknown
- 1981-01-09 FI FI810056A patent/FI76927C/fi not_active IP Right Cessation
-
1982
- 1982-01-29 ES ES509179A patent/ES509179A0/es active Granted
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0287488B1 (fr) | Médicament, produit diététique et produit d'hygiène sous la forme d'une composition pulvérulente obtenue par adsorption de principes actifs sur un sucre à dissolution rapide et procédé d'obtention de ladite composition | |
| CH646604A5 (fr) | Composition pharmaceutique a effet prolonge et son procede de fabrication. | |
| CA2825053C (fr) | Granules effervescents d'acide gamma-hydroxybutyrique | |
| US4308251A (en) | Controlled release formulations of orally-active medicaments | |
| EP2349217A1 (fr) | Nouvelle composition à base d'acide gamma-hydroxybutyrique | |
| EP0065531A1 (fr) | Nouvelle forme galenique du fenofibrate, son procede d'obtention, son application comme medicament | |
| JP2003055203A (ja) | ユビキノン含有製剤 | |
| CH647676A5 (fr) | Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation. | |
| JPH11286441A (ja) | イブプロフェン組成物 | |
| JPS63107917A (ja) | イブプロフエン徐放性製剤およびその製造方法 | |
| MX2007016072A (es) | Formulaciones de diclofenac y metodos para usarlas. | |
| HU198621B (en) | Process for producing easily administrable pharmaceutical compositions comprising antibacterial active ingredient, with regulated release of active ingredient | |
| FR2541287A1 (fr) | Preparation stable administrable par voie orale de macrolides antibiotiques et procede pour les stabiliser | |
| JP4668513B2 (ja) | 粒状化可能な混合物の調製方法及びカルニチン・マグネシウム・ヒドロキシクエン酸塩 | |
| FR2524314A1 (fr) | Medicament a action salidiuretique, contenant des dihydropyridines | |
| EP1469835B1 (de) | Stabile salze von o-acetylsalicylsäure mit basischen aminosäuren ii | |
| FR2529784A1 (fr) | Medicament a liberation retardee contenant du 1-(p-(isopropylthio)-phenyl)-2-octylamino-1-propanol | |
| FR2467596A1 (fr) | Compositions pharmaceutiques de tiaramide ou de son sel et d'un agent reglant la dissolution, a longue duree d'action | |
| EP0483320B1 (fr) | Compositions pharmaceutiques du type a liberation prolongee destinees a l'administration par voie orale et leur procede de preparation | |
| JPH11322584A (ja) | ベザフィブラート徐放性製剤 | |
| RU2155032C1 (ru) | Способ получения лекарственной формы противовоспалительного симптоматического действия | |
| RU2233155C1 (ru) | Способ получения витаминного комплекса в виде драже | |
| EP0412877A1 (fr) | Nouvelle forme galénique orale améliorant la biodisponibilité | |
| CA2182024C (fr) | Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees | |
| NO175185B (en, 2012) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |